Immunomagnetic reduction assay on des-gamma-carboxy prothrombin for screening of hepatocellular carcinoma

Jen Jie Chieh*, K. W. Huang, C. P. Chuang, W. C. Wei, J. J. Dong, Y. Y. Lee

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


The accredited biomarker alpha-fetoprotein (AFP) offers limited sensitivity and specificity in the early detection of hepatocellular carcinoma (HCC). To improve the screening performance, des-gamma-carboxy prothrombin (DCP) has been identified as another promising biomarker of HCC, combined with AFP biomarkers. The results of the commercial optical enzyme-linked immunosorbent assay (ELISA) kit easily have the interference problem due to the optical methodology. The immunomagnetic reduction (IMR) assay based on the magnetic measurement was utilized to assay DCP biomarkers without the excellent antiinterference performances. A DCP magnetic reagent, composed of iron-oxide (Fe3O4) magnetic nanoparticles coated with anti-DCP antibodies solved in phosphoryl-buffer solution, was synthesized and characterized. In the test of standard DCP antigens, superior antiinterference and sensitivity than optical ELISA were proved. In the animal test, the results indicate good agreement between the IMR assay findings and the tumor sizes of HCC rats at all time points after the HCC implantation. The feasibility of the developed DCP magnetic reagent with the IMR for the detection of DCP is verified, and demonstrates the high potential for future clinical applications.

Original languageEnglish
Article number7273866
Pages (from-to)1681-1686
Number of pages6
JournalIEEE Transactions on Biomedical Engineering
Issue number8
Publication statusPublished - 2016 Aug


  • Des-gamma-carboxy prothrombin
  • enzyme-linked
  • hepatocellular carcinoma
  • immunomagnetic reduction
  • immunosorbent assay

ASJC Scopus subject areas

  • Biomedical Engineering


Dive into the research topics of 'Immunomagnetic reduction assay on des-gamma-carboxy prothrombin for screening of hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this